Search

everythinglearnresearchcommunity

for

Search:↓

Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.

Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.

Some people developed alopecia areata after COVID-19 vaccination, but it's not caused by the vaccine and most improved with treatment.

CAR is a useful marker for assessing alopecia areata severity.

Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.

Both azathioprine and betamethasone treatments effectively regrow hair in alopecia areata, but azathioprine may be safer.

Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.

Sequential therapy with dupilumab and baricitinib improved hair regrowth and atopic dermatitis in a child without adverse reactions.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.

Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.

There's no strong link between Alopecia Areata, a hair loss condition, and fatty liver, but more research is needed.

Children with alopecia areata often have low vitamin D, especially if they have darker skin, it's not summer, or they're not White.

Standard intralesional corticosteroids are the best treatment for patchy alopecia areata.

Both azathioprine and betamethasone treatments help with hair regrowth in alopecia areata, but azathioprine may have fewer side effects.

Betamethasone is more effective for hair regrowth than latanoprost but has more side effects.

Combining platelet-rich plasma and minoxidil can effectively regrow hair in severe alopecia areata cases.

Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.

Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.

CD8+ T cells are involved in alopecia areata and may cause disease relapse.

Alopecia areata severity and treatment response are linked to specific cytokine levels.

Low vitamin D might be linked to certain types of hair loss, and supplements could help, but more research is needed.

Most hair loss disorders can be accurately diagnosed and treated in an outpatient setting.

Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.

Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.

Nivolumab can cause hair loss as a rare side effect.

Mesalazine may help treat extensive alopecia areata effectively.

Some people with a history of autoimmune hair loss experienced worsening symptoms after COVID-19 vaccination.

Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.

Higher CD70 and CD27 gene expression in alopecia areata lesions predicts disease severity and activity.